Although treatment with recombinant IGF‐1 in the elderly is currently not recommended due to a potentially increased risk for cancer, other treatment options that increase vascular IGF‐1 signaling, attenuate vascular ROS production, and/or reduce MMP activation could be considered for cerebromicrovascular protection in older individuals at risk for CMHs. This evidence concerns the gene IGF1 and cancer.